Revance Therapeutics (RVNC) Misses Q4 EPS by $1.08

Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($1.82), $1.08 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $49.9 million versus the consensus estimate of $44.91 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• JPMorgan Downgrades Wipro Ltd. (WPRO:IN) (WIT) to Underweight
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat